Cargando…
Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
BACKGROUND: Tofacitinib is a small molecule that inhibits Janus kinase and has been reported to be effective in Western patients with ulcerative colitis (UC). However, the real-life data on tofacitinib in Asian UC patients are limited. OBJECTIVE: To investigate the real-life effectiveness and safety...
Autores principales: | Shin, Seung Hwan, Oh, Kyunghwan, Hong, Sung Noh, Lee, Jungbok, Oh, Shin Ju, Kim, Eun Soo, Na, Soo-Young, Kang, Sang-Bum, Koh, Seong-Joon, Bang, Ki Bae, Jung, Sung-Ae, Jung, Sung Hoon, Kim, Kyeong Ok, Park, Sang Hyoung, Yang, Suk-Kyun, Choi, Chang Hwan, Ye, Byong Duk |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026122/ https://www.ncbi.nlm.nih.gov/pubmed/36950251 http://dx.doi.org/10.1177/17562848231154103 |
Ejemplares similares
-
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
por: Oh, Kyunghwan, et al.
Publicado: (2023) -
Corrigendum: Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
por: Oh, Kyunghwan, et al.
Publicado: (2023) -
Clinical Characteristics of Microscopic Colitis in Korea: Prospective Multicenter Study by KASID
por: Park, Young Sook, et al.
Publicado: (2011) -
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
por: Shin, Seung Yong, et al.
Publicado: (2022) -
Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
por: Lee, Jin Wook, et al.
Publicado: (2021)